
|Videos|August 11, 2014
Dr. Brufsky Discusses Future Research into Bisphosphonates
Author(s)Adam M. Brufsky, MD, PhD
Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses future research into bisphosphonates.
Advertisement
Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses future research into bisphosphonates.
The cancer cell itself is incredibly complex, Brufsky says. Much work has been done to understand cancer cells with next-generation sequencing and RNA-based assays.
Drugs like bisphosphonates and denosumab affect the host greatly. Research needs to be conducted focused on the genomics of the host and the factors that allow metastatic disease to come about from the host’s perspective.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Sacituzumab Govitecan Monotherapy and In Combination With Pembrolizumab in Frontline TNBC
2
Dr Tolaney on the FDA Approval of First-Line Sacituzumab Govitecan Plus Pembrolizumab for TNBC
3
Daratumumab Retreatment Displays Activity in Relapsed Myeloma Following Continuous Frontline Therapy
4
Dr Morgans on the Design of the ARACOG Trial in Prostate Cancer
5



















































































